FBLG: Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 1Q26

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Approval from HREC for Phase 1/2 Diabetic Foot Ulcer Trial In ...
Le Lézard

INTENT Biologics Receives FDA Fast Track Designation for PEP Biologictm

INTENT Biologics, a clinical-stage biotechnology company developing first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced today that the ...